Elliot Wilbur
Stock Analyst at Raymond James
(1.30)
# 3,410
Out of 4,854 analysts
55
Total ratings
32.61%
Success rate
-1.43%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $25 → $32 | $19.94 | +60.48% | 8 | May 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $59.88 | +38.61% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $60 → $40 | $7.23 | +453.25% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $9.19 | +259.09% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $25.97 | +65.58% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $3.16 | +3,697.47% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $8.46 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $17.25 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $168.61 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $13.43 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $7.57 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $25.52 | - | 3 | Nov 9, 2017 |
ADMA Biologics
May 8, 2025
Maintains: Strong Buy
Price Target: $25 → $32
Current: $19.94
Upside: +60.48%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $59.88
Upside: +38.61%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $60 → $40
Current: $7.23
Upside: +453.25%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $9.19
Upside: +259.09%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $25.97
Upside: +65.58%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $3.16
Upside: +3,697.47%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $8.46
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $17.25
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $168.61
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $13.43
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $7.57
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $25.52
Upside: -